**ARCTIC AND ANTARCTIC BIODIVERSITY: IMPLICATIONS FOR PHARMACOLOGY AND ANTIMICROBIAL RESISTANCE**

**ABSTRACT:**

Research into Arctic and Antarctic pharmacology deals with the peculiar pharmaceutical potential of polar organisms. Highly extreme environments, such as those of the polar regions, harbor many species, including marine organisms and fungi, that synthesize novel bioactive compounds of significant therapeutic interest, especially against antimicrobial resistance a global health crisis. Marine terpenoids and fungal products from polar regions were promising for antimicrobial, antiviral, or antitumor purposes. Polar organisms have so far evolved to tolerate extreme cold, low light intensities, and high ecological pressure; the result is that secondary metabolites developed are extraordinarily equipped with bioactivity. Through these compounds, such organisms thus turn out to be efficient in treating infections and show potential for anticancer and anticancer therapy. Vitamin D deficiency occurs by large in most Arctic inhabitants since they receive minimal sunshine and exposure. This gave rise to the study on supplementation regimes and the formulation of drugs tailored for polar environments. All these discoveries hold high value in the management of health care of indigenous Arctic populations and Antarctic researchers and military men stationed in these areas. Drug development in Arctic medicine necessitates rigorous research, moral bio-prospecting, sustainable procedures, and cooperation between researchers, healthcare practitioners, politicians, and local communities. Polar pharmacology, a field that rapidly emerged, is providing ready-to-translate insights into the treatment of infections caused by drug-resistant pathogens and other health issues related to extreme environments. It can further unlock more resources for answering unmet medical needs in pursuit of broad public health outcomes.

**Keywords:** Polar Latitude, Marine Source, Anesthesia, Vitamin D, Antimicrobial Resistance, Drug Development.

**1****. INTRODUCTION**

Research in pharmacology encounters unique challenges and opportunities due to the harsh environments and diverse ecosystems of the Arctic and Antarctic. Polar organisms have become crucial in studying rapidly changing climate conditions in these regions. Genomics, in particular, offers unprecedented insights into the unique adaptations and fundamental biological principles of these organisms. Assessing polar biodiversity through multi-omics approaches is essential for understanding the evolution of life in permanently cold environments.[1] Some polar organisms exhibit extraordinary adaptations that allow them to survive in extreme conditions, which has led to the biosynthesis of novel bioactive molecules.[2] Polar microorganisms, especially, have shown promising potential as sources of new natural medicines and biological agricultural chemicals. Cold-adapted bacteria and fungi from polar regions possess broad antibacterial characteristics, producing chemicals that are effective against a wide range of diseases.[3] These organisms, particularly from Antarctica, have immense potential in combating antimicrobial resistance. Although relatively few patents currently exist, the diversity of species and compounds from polar biota suggests significant potential for future antimicrobial discoveries.[4] The polar regions are among the harshest and most isolated places on Earth, where the unique climate and intense ecological competition foster the production of compounds with diverse biological activities.[5] The field of Arctic pharmacology specifically examines the effects and applications of medications in cold climates.

Health concerns common among Arctic populations include infectious diseases, malnutrition, and mental health disorders. This field explores the development of drugs tailored to these specific conditions, as extreme cold, limited healthcare access, and indigenous communities present unique challenges.[6] In providing appropriate treatments for isolated Arctic populations, pharmacological research also investigates how environmental conditions affect medication efficacy and safety. Research in this area addresses health issues relevant to Antarctic residents, researchers, and visitors, recognizing that the Antarctic climate-while distinct from the Arctic in its isolation, extreme temperatures, and unique ecosystems-presents similar challenges.[7]

**2. POLAR LATITUDE MARINE TERPENOIDS**

Extremes in temperature, light photoperiod, and ice disturbance, combined with biological interactions, have led to the selection of species with a unique suite of secondary metabolites, allowing the polar marine biota to thrive in one of the most inhospitable habitats known in the ocean.[8] Arctic organisms and Antarctic oceans are rich sources of natural resources, with exceptional bioactivities for human use and a wide range of structural diversity.[9] The most commonly identified chemicals are chemical skeletons from the terpene family, and the most thoroughly described activity from these environments is the ability to fight infections via cytotoxic antimicrobial properties.[10] Terpene and terpenoid derivatives appear to be the most regularly reported compounds with pharmacological potential isolated from Arctic and Antarctic marine species, based on published data.[11] Furthermore, these chemical classes frequently exhibit exceptional antimicrobial capabilities, including antiviral and anticancer activity.[12] Such cytotoxic responses are most likely in response to harmful effects caused by terpenoids. Thus, marine creatures from the polar regions could make a significant contribution to the growing repertoire of promising bioactive chemicals.[13]

**3. DIVERSITY OF CULTIVABLE FUNGAL**

In Antarctica, fungi can be found in a wide range of environments. Despite harsh environmental conditions, the fungal communities that inhabit lakes are renowned for their richness.[14] [15] From Antarctic Lake sediments, researchers recovered 195 fungal isolates. These isolates were identified as belonging to 42 taxa in the Ascomycota, Basidiomycota, and Mortierellomycota, with the most common being the lebolusglobosus, Antarctomyces psychrotrophic, Pseudogymnoascus verrucosus, Vishniacozymavictoriae, and Phenoliferia sp. [16]

**3.1 BIO PROSPECTION**

Antarctica has a total area of 13. Distributing over 8 km 2 with various terrestrial and marine ecological systems. But Antarctica has different environments, so different cold cosmopolitan, and endemic microorganisms are found here.Bioprospecting research using Antarctic microorganisms has intensified in the last few years. Among most of them, fungi have proved their perspectives on bio products’ relevance in medicine, industry, and agriculture.[17] The mean baseline 25(OH)D level was 64.9 ± 19.1 nmol/L. A full stay had an overall effect of -15.0 nmol/L (95% CI: -25.9, -4.2; P = 0.007) on mean 25(OH)D. The funnel plot shows that there was no publication bias in the study. However, much research has been done on the biodiversity of fungi worldwide, and an estimate of their species has been made. A surprising diversity of fungal species has been discovered via the development of molecular phylogeny, and the use of culture-independent techniques such as high throughput amplicon sequencing has significantly expanded the number of fungal operational taxonomic units. By using molecular phylogeny, many cryptic species were also identified. Data collected and generated from independent and culture-dependent studies have shown that there are now 13.2 million fungal species on Earth, up from a previous estimate of 2.2 to 3.8 million.[19] Fungal variety is a fundamental component of nature that not only monitors the environment but also plays a role in agriculture, medicine, pharmacology, industry, food, technology, and other biotechnological fields. Fungi are well known for their capacity to colonize a wide range of settings and reproduce naturally. One-third of the world's fungal variety is found in India. However, fungal taxonomists are becoming increasingly scarce, posing a threat to the discovery of hidden fungal wealth. Some fungi have also become extinct, necessitating mycologists' monitoring to ensure their survival.[20]

**4. ANTIMICROBIAL SUBSTANCES DERIVED FROM ANTARCTIC ORGANISMS**

Any natural, synthetic, or semi-synthetic substance that can combat germs is referred to as an antimicrobial.[21] [22] The golden age of antibiotic therapy began with the discovery of penicillin and was characterized by the discovery of several natural compounds with unique mechanisms of antimicrobial activity. These compounds' introduction into clinical practice has significantly increased human life expectancy and quality.[23] [24] There are currently resistance mechanisms in place against every class of antimicrobial medication.[25] The World Health Organization (WHO) has estimated that antibiotic-resistant diseases are a global public health concern that currently results in approximately 700,000 annual fatalities and may escalate to 10 million deaths annually by the year 2050.Examining patent patterns in antimicrobial chemicals derived from Antarctic species, the study focuses on researchers, global geography, and medical applications. When it comes to studying and patenting antimicrobials from Antarctica, the US, South Korea, and China are the most involved.[26]

**5. ANTARCTIC MARINE NATURAL PRODUCTS**

Natural compounds have significant ecological and medicinal potential and are consequently widely found in Antarctic organisms. However, there is still more research to be done on the possible uses of marine natural compounds in pharmacy.[27] Chemical defenses are a tactic used by many Antarctic marine species to fend off predators. The natural substances that exhibit the pharmacological effects that have been noted, such as antibacterial, anti-inflammatory, and anticancer properties, have not yet been found. At depths between 200 and 500 meters, ecologically active species are more frequently observed, and sessile creatures are almost four times more likely than mobile organisms to have chemical defenses against predators.[28] Some naturally occurring marine compounds are utilized, among other things, as analgesics to relieve inflammationor as anticancer medications.[29] With a wide range of bioactivities, Antarctic marine benthic crustaceans represent a valuable but understudied source of natural products. Only above 3% of the marine natural products have so far been found to originate from the polar areas, where, despite great diversity and chemo diversity of Antarctic marine life, it is found that a significant amount of potential remains unrealized. This biodiversity and chemo diversity, therefore, forms the basis for exploiting entirely the advantages of Antarctic marine natural goods when managed sustainably. Hence, there is a demand for supply issues to be addressed, and speed up the discovery process, and come down the cost of research. [30] Only a tiny portion of the numerous bioactive substances identified from the seas have been investigated for their ecological importance. Similarly, because the chemicals involved are yet unknown, the majority of chemical-mediated interactions are poorly understood. Although polar species are equally prolific manufacturers of chemical barriers, and pharmacologically relevant compounds are being documented from the Southern Ocean, this information gap is much more pronounced in Antarctica than in tropical or temperate regions. It is anticipated that newly discovered functional secondary metabolites will be selected by the harsh and distinctive maritime conditions around Antarctica as well as the many odd interactions occurring in benthic organisms. [31] Indeed, some research indicates that marine creatures yield a greater quantity of bioactive natural compounds compared to terrestrial animals.[32]

**5.1 ECOLOGICAL ACTIVITY**

Using the common, eurybathic, and generalist sea star *O. validus*, the possible ecological action of extracts from marine benthic species against a macropredator was determined.[33] This sea star is a useful model for conducting repellence bioassays using our previously outlined methodology because it is a common sympatric predator.[34] Protection from *O. validus* predation is assessed along depth gradients of sample collection, taking into account the organisms' vagile or sessile lifestyles.[35] Human activity-related chemical and sewage pollution in Antarctica is a persistent problem, and existing sewage treatment techniques are insufficient to stop local contamination. The Antarctic flora and fauna have been disrupted by human activities such as building and transportation, and a few non-native species have established themselves, mostly in the southern Scotia Arc and northern Antarctic Peninsula. Fishing operations may have significant effects on accidental capture species and the larger environment, and overfished fish populations in Antarctica have not shown much indication of recovery.[36]

**5.2 PHARMACOLOGICAL ACTIVITY**

Consideration is given to the pharmacological activity of the antibacterial, anti-inflammatory, and anticancer qualities assessed in recent projects. These investigations tested several materials against human tumor cell lines (HT-29, A-549, and MDA-MB 231) and anti-inflammatory properties. Measurements of the anti-inflammatory activity included a decrease in the synthesis of several inflammatory mediators, such as prostaglandin E2, leukotriene B4, and interleukin-1β. [37] More than 125,000 natural product extracts are available in the fractionation library of the National Cancer Institute's natural product discovery program for screening against disease states to reinvigorate natural product-based discovery.38] Diverse cultivable fungi from Antarctic lake benthic mats produce novel antimicrobial and cytotoxic compounds.[39] Antarctic macroalgae host diverse and complex fungal communities that may be a source of bioactive compounds. The most common taxa were Geomyces species (sp.), Penicillium spp., and Metschnikowia australis.[40] Marine fungi colonize a diverse spectrum of organic substrates, including sponges, corals, echinoderms, vertebrates, and algae. The research of fungal species diversity in marine algae is in its early stages, yet these microorganisms are particularly interesting due to their ecological significance.[41]

**6. ANTIOXIDANT PROPERTIES OF ANTARCTICA'S *SANIONIA UNCINATE***

Antioxidant medicines can cure oxidative illnesses by scavenging oxygen, chelating catalytic metals, and neutralizing reactive oxygen species (ROS).[42] Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), Propyl Galate, and Tetra butyl hydroquinone are the most often utilized antioxidants. Furthermore, several publications have been released on the synthesis of substances with potent antioxidant qualities. The creation of potent antioxidants using a natural source is very desirable due to the significant carcinogenicity of synthetic antioxidants.[43] Sanionia uncinata, an Antarctic moss, has shown promise for photoprotection and strong antioxidant qualities. Research has demonstrated that S.*uncinata* extracts can scavenge free radicals; the superoxide, IC50 values for DPPH, and ABTS cation scavenging range from 181.3 to 466.2 µg/Ml.[44] The moss contains various flavonoids and phenolic compounds that enhance its antioxidant activity. Extracts have been proven to possess defense mechanisms against DNA breakage caused by reactive oxygen species, especially by superoxide and hydroxyl radicals. In addition, the extracts of S. *uncinata* exhibited photoprotective activities against UV radiation, such as UV-C and UV-A, with no reported phototoxicity or mutagenicity. Compared with hydroethanolic extract, aqueous extract has been reported to offer better protection against thymine dimerization caused by UV radiation. These results may make it possible to suggest that S. *uncinata* may be a good organic source of antioxidants and photoprotectors useful in medicine and cosmetics.[45]

**7. ANTARCTIC AND SUB-ANTARCTIC: ANTITUMOURAL ACTIVITY**

A prospecting search for antitumoral activity in polar benthic crustaceans was conducted in three locations: sub-Antarctic Bouvet Island, the Antarctic's eastern Weddell Sea, and the Antarctic's South Shetland Islands. Marine environments are regarded to be the most important potential sources of biodiversity on Earth. The largest pharmacological study of marine benthic invertebrates from the Antarctic and sub-Antarctic ever carried out. Sessile marine invertebrates from all over the world have been studied, and it has been found that these animals are more prone to creating harmful compounds.[46] Antarctica contains the South Shetland Islands, the Eastern Weddell Sea, and Bouvet Island. Three human tumor cell lines were used to evaluate the pharmacological potential of 770 benthic invertebrate samples (covering at least 290 diverse species) from 12 different phyla. Bioassays revealed anticancer activity in 15 unique species from five different phyla: Tunisia (5), Porifera (4), Cnidaria (3), Echinodermata (2), and Annelida (1).[47]

**8. IN NORWEGIAN, ACUTE MYOCARDIAL INFARCTION IS TREATED**

Acute Myocardial Infarction (AMI)-)-related disability and mortality rates may be reduced with the right therapies.[48] The prevalence of cardiovascular disease (CVD) and associated lifestyle factors varies globally.[49] Studies on how these patterns relate to one another over time suggest that changes in lifestyle factors occur before changes in CVD outcomes. Effective cardiovascular treatment may potentially be responsible for a decline in the death rate from CVD.[50] It has long been known that AMI is more common in northern Norway, especially in Finn Mark County.[51] Investigating how Acute Myocardial Infarction (AMI) is managed in Northern Norway, comparing it to national data, and documenting whether or not a comparable standard of care exists were the goals. The retrospective analysis included information on patients' AMI therapy. The following sources were consulted. The Norwegian Patient Registry, the National Quality of Care Database, the Norwegian Myocardial Infarction Registry, and the National Air Ambulance Services of Norway. AMI incidence, age- and gender-adjusted AMI rates, revascularization (PCI, CABG) according to the patient's residency, and 30-day survival rate were the variables that were examined throughout the 2012–2014–2015 study period. The yearly occurrence of AMI was 9% greater in the northern climate.[52]

**9. COULD YOU TAKE ANESTHESIA PRESCRIPTIONS IN ANTARCTICA?**

Physicians in general may be required to work in unfamiliar or difficult locations in which medical resources get depleted or medicine efficacy is altered due to environmental conditions.[53] These conditions can introduce uncertainty into anesthetic techniques, affecting patient safety.[54] Antarctica is the continent with the lowest temperatures, the most wind, and the highest elevation. It is one of the most remote areas on the planet, with some of the harshest natural conditions.[55] In these difficult weather conditions, the medical capacities of numerous military stations and warships are limited.[56] Anesthesiologists may be required to operate in unfamiliar or complicated settings where the availability of medical supplies is reduced or medication efficacy is changed owing to external circumstances. These circumstances may increase the level of ambiguity in the anesthetic plan, which may affect patient safety.[57]

**10. ANTARCTICA'S VITAMIN D LEVEL AND SUPPLEMENTATION**

Vitamin D insufficiency affects a large portion of the global population. Vitamin D insufficiency can cause bone mineralization defects, resulting in 1000000 osteomalacia in adults and rickets in children.[58] [59] Vitamin D deficiency is caused by insufficient sun exposure, particularly at higher latitudes, which reduces skin production during the winter. Sunlight may be insufficient for year-round VD synthesis in high circumpolar latitudes.[60] [61] Solar UV radiation in Antarctica is shallow at high latitudes and low elevation angles, notwithstanding the stratosphere ozone layer hole.[62] [63] Residents spend the majority of their time indoors due to the frigid weather and severe polar climate. Both year-round or overwintering inhabitants and shorter visits make up the two categories of seasonal stays in Antarctica, which vary greatly. During visits to the Antarctic, food choices and dietary practices have an impact on vitamin D levels. Deficit in vitamin D is generally increased by harsh weather and little sun exposure. Humans in Antarctica benefit from vitamin D supplements, which can improve their Vitamin D status and may even be required for expeditions with restricted access to UVB radiation.[64]

**10.1 VITAMIN D STATUS FOR THE ENTIRE ANTARCTIC STAY**

The status of vitamin D has been significantly decreased after occupying Antarctica, especially during winter; supplementation improves this status.[65] Humans in Antarctica face a variety of environmental obstacles, including minimal UV radiation, which is necessary for vitamin D generation in humans. Elevated vitamin D levels in the blood may safeguard against future deficiencies. Living in the Neumayer Stations may result in lower serum vitamin D levels than in other equivalent high latitudes.[66] These people, particularly space travelers, are at risk since they have had little exposure to UVB light. New evidence suggests that blood 25-hydroxyvitamin D levels should be more than or equal to 80 nmol/L.[67] A meta-analysis of 10 studies on the impact of Antarctic residents on vitamin D status found that a whole stay in Antarctica significantly lowered the body's vitamin D status. The mean baseline 25(OH)D level was 64.9 ± 19.1 nmol/L. A full stay had an overall effect of -15.0 nmol/L (95% CI: -25.9, -4.2; P = 0.007) on mean 25(OH)D. The funnel plot shows that there was no publication bias in the study. The findings imply that living in the Antarctic considerably lowers vitamin D levels.[68]

**11. ANTARCTICA - ANTIMICROBIAL RESISTANCE**

A worldwide worry is the quick spread of antibiotic resistance to microorganisms in Antarctic fauna. Antibiotic resistance was found in 80% of the isolates of bacteria from Antarctic animals. Common gut microorganisms such as Enterobacteriaceae and Enterococcus were among the resistant bacteria. Due to their wide variety of antibiotic resistance, penguins and pinnipeds may be used as sentinels for future research.[69] One significant issue facing world health is Antimicrobial Resistance (AMR).[70] Antarctica is one place on Earth where surveillance is very lacking. Although this far-off, harsh environment is not known to be a hotspot for antimicrobial resistance, comparatively pure areas with minimal levels of human habitation can serve as easier model systems for researching the elements that spread antimicrobial resistance. Examining AMR in these domains can help determine how much human activities have contributed to the spread of antibiotic-resistant bacteria and antimicrobial-resistance genes.[71] In Antarctica, AMR is more common around research sites, while it seems to be low in the indigenous fauna. Anthropogenically introduced AMR is still absent from Antarctica's least populated areas. Inconsistent reporting standards, methods, and inadequate geographic coverage of the data make it impossible to thoroughly evaluate AMR levels in Antarctica.[72]

**11.1 ENDEMIC AMR**

Antibiotic Resistance (AMR) is inevitable, even in pristine places such as Antarctica.[73] In Antarctic bacteria found in pristine environments such as freshwater lakes, soils, phytoliths, and glacial ice cores, antibiotic-resistant genes have been detected in low quantities.[74] Remoteness in harsh environments like Antarctica is believed to have a far less detrimental impact on humans than in many other parts of the world, even though the rate at which antimicrobial resistance is spreading alarms, particularly about clinical environments, is rising in many parts of the world. Antarctica is frequently regarded as the planet's final unspoiled continent. The mechanisms and interactions underlying the early stages of the evolution process, de novo development, acquisition, and transmission of AMR can likely be better understood in such remote regions, which are thought to have very low levels of AMR due to limited human activity. With great populations of migrating birds and other animals in addition to well-defined areas of human settlement and scientific research sites, Antarctica holds great promise for the tracking and understanding of early-stage zoonotic interactions. However, there are very few studies on AMR in Antarctica today.[75] Since antibiotics are naturally created in hostile environments as defensive mechanisms, broad-spectrum resistance is a result of these extreme environmental conditions.[76] From the widespread use of antibiotics, antibiotic resistance in aquatic bacteria has increased steadily, whereas antibiotic contamination in Antarctica should have been limited by practice and international treaties.[77]

**11.2 ANIMAL VECTORS OF AMR IN ANTARCTICA**

One important area of unanswered research is how charismatic megafauna in Antarctica affect antimicrobial resistance (AMR). There is little information on wildlife as AMR vectors, but it is known that people and animals may cooperate to transfer antibiotic-resistant genes.[78] The gut flora of arctic fauna, especially birds, was first studied in 1899.[79] Bacteria from pigeon intestines and other animals were easily isolated as molecular biology and culture techniques advanced.[80] Warm-blooded marine animals in Antarctica harbor clinically relevant antimicrobial resistance determinants, indicating ocean pollution with antibiotic-resistant bacteria. [81]

**12. DRUG DEVELOPMENT METHODOLOGY IN ARCTIC MEDICINE**

Issues relating to biology and medicine are closely associated with the development and exploration of the Arctic areas.[82] Medical devices, drugs, and prophylactics must be designed and developed for use in the Arctic.[83] Even with all of the knowledge and experience that has been gathered, there is still no tried-and-true set of procedures for determining the effects of cold on an animal's body.This is also the case for in vivo studies of hypoxic conditions; the photoperiod plays an important role in these situations, but it is frequently disregarded.[84] When designing medications for use in the Arctic, it is especially crucial to consider how best to optimize the injectable drug's characteristics through the use of cryoprotectants. The question of adaptive development is another important one to emphasize.[85] Inextricable is the relation between the exploration and the development of Arctic territories with the developing associated problems of a medical-biological nature. It is necessary to design and develop the drugs for emergency care and prevention medical devices that would be used in the Arctic.[86]

**13. CONCLUSION**

Research and ethical bio-prospecting are crucial for utilizing the potential of extreme environments like Antarctica. Sustainable practices and advanced technologies can develop new treatments for infectious diseases and antibiotic resistance. Collaborative efforts among researchers, healthcare providers, policymakers, and local communities are essential for navigating complex drug development in Arctic medicine.

**REFERENCES:**

1. Clark MS, Clarke A, Cockell CS, Convey P, Detrich III HW, Fraser KP, Johnston IA, Methe BA, Murray AE, Peck LS, Römisch K. Antarctic genomics. Comparative and functional genomics. 2004 Apr;5(3):230-8.
2. Tian Y, Li YL, Zhao FC. Secondary metabolites from polar organisms. Marine drugs. 2017 Feb 23;15(3):28.
3. Lo Giudice A, Fani R. Antimicrobial potential of cold-adapted bacteria and fungi from polar regions. Biotechnology of Extremophiles: Advances and Challenges. 2016:83-115.
4. Silva MB, Feitosa AO, Lima IG, Bispo JR, Santos AC, Moreira MS, Camara PE, Rosa LH, Oliveira VM, Duarte AW, Queiroz AC. Antarctic organisms as a source of antimicrobial compounds: a patent review. Anais da Academia Brasileira de Ciências. 2022 Mar 25;94:e20210840.
5. Liu JT, Lu XL, Liu XY, Gao Y, Hu B, Jiao BH, Zheng H. Bioactive natural products from the antarctic and arctic organisms. Mini reviews in medicinal chemistry. 2013 Apr 1;13(4):617-26.
6. Sonne C, Dietz R, Jenssen BM, Lam SS, Letcher RJ. Emerging contaminants and biological effects in Arctic wildlife. Trends in Ecology & Evolution. 2021 May 1;36(5):421-9.
7. Hueffer K, Ehrlander M, Etz K, Reynolds A. One health in the circumpolar North. International journal of circumpolar health. 2019 Jan 1;78(1):1607502.
8. Hurst, D.; Børresen, T.; Almesjö, L.; De Raedemaecker, F.; Bergseth, S. Marine Biotechnology Strategic Research and Innovation Roadmap: Insights to the Future Direction of European Marine Biotechnology; Marine Biotechnology ERA-NET: Oostende, Belgium, 2016.
9. Nunez-Pons, L.; Avila, C.; Romano, G.; Verde, C.; Giordano, D. UV-protective compounds in marine organisms from the Southern Ocean. Mar. Drugs **2018**, 16, 336.
10. Angulo-Preckler, C.; Spurkland, T.; Avila, C.; Iken, K. Antimicrobial activity of selected benthic Arctic invertebrates. Polar Biol. **2015**, 38, 1941–1948.
11. Núñez-Pons, L.;Avila, C. Natural products mediating ecological interactions in Antarctic benthic communities:
12. A mini-review of the known molecules. Nat. Prod. Rep. **2015**, 32, 1114–1130.
13. Soldatou, S.; Baker, B.J. Cold-water marine natural products, 2006 to 2016. Nat. Prod. Rep. **2017**, 34, 585–626.
14. [Ogaki, M.B., Vieria, R., Lirio, J.M., Rosa, C.A., Rosa, L.H., 2019b. Diversity and ecology of fungal assemblages present in lakes of Antarctica. In: Rosa, L.H. (Ed.), Fungi of Antarctica. Springer Nature Switzerland, pp. 69e97.](http://refhub.elsevier.com/S1878-6146%2820%2930035-0/sref44)
15. Ogaki MB, Teixeira DR, Vieira R, Lírio JM, Felizardo JP, Abuchacra RC, Cardoso RP, Zani CL, Alves TM, Junior PA, Murta SM. Diversity and bioprospecting of cultivable fungal assemblages in sediments of lakes in the Antarctic Peninsula. Fungal biology. 2020 Jun 1;124(6):601-11.
16. Ogaki MB, Teixeira DR, Vieira R, Lírio JM, Felizardo JPS, Abuchacra RC, Cardoso RP, Zani CL, Alves TMA, Junior PAS, Murta SMF, Barbosa EC, Oliveira JG, Ceravolo IP, Pereira PO, Rosa CA, Rosa LH. Diversity and bioprospecting of cultivable fungal assemblages in sediments of lakes in the Antarctic Peninsula. Fungal Biol. 2020 Jun;124(6):601-611. doi: 10.1016/j.funbio.2020.02.015. Epub 2020 Mar 6. PMID: 32448451.[.](http://refhub.elsevier.com/S1878-6146%2820%2930035-0/sref50)
17. [Woo, S.L., Ruocco, M., Vinale, F., Nigro, M., Marra, R., Lombardi, N., Pascale, A., Lanzuise, S., Manganiello, G., Lorito, M., 2014. Trichoderma-based products and their widespread use in agriculture. Open Mycol. J. 8, 71e126.](http://refhub.elsevier.com/S1878-6146%2820%2930035-0/sref69)
18. Sette LD, Pagnocca FC, Rodrigues A. Microbial culture collections as pillars for promoting fungal diversity, conservation and exploitation. Fungal Genetics and Biology. 2013 Nov 1;60:2-8.
19. Manoharachary C, Sridhar K, Singh R, Adholeya A, Suryanarayanan TS, Rawat S, Johri BN. Fungal biodiversity: distribution, conservation and prospecting of fungi from India. Current Science. 2005 Jul 10:58-71.
20. Manoharachary C, Kunwar IK, Tilak KV. Diversity and characterization of fungi and its relevance. Indian Phytopath. 2013 Jun 26;66(1):10-3.
21. GENILLOUD O. 2014. The re-emerging role of microbial natural products in antibiotic discovery. Anton Leeuw Int J G 106(1): 173-188.
22. BROWN ED & WRIGHT GD. 2016. Antibacterial drug discovery in the resistance era. Nature 529(7586): 336-343.
23. AMINOV R. 2017. History of antimicrobial drug discovery: Major classes and health impact. Biochem Pharmacol 133: 4-19.
24. LIVERMORE DM. 2009 Has the era of untreatable infections arrived? J Antimicrob Chemother 64(1): 29-36.
25. GUIMARÃES DO, MOMESSO LS & PUPO MT. 2010. Antibióticos: importância terapêutica e perspectivas para a descoberta e desenvolvimento de novos agentes. Quim -Nova 33(3): 667-679.
26. MARIOTTINI G & GRICE I. 2016. Antimicrobials from Cnidarians. A New Perspective for Anti-Infective Therapy? Mar Drugs 14(3): 48.
27. Ávila, C., & Angulo–Preckler, C. (2021). A Minireview on Biodiscovery in Antarctic Marine Benthic Invertebrates. *Frontiers in Marine Science*.Ávila, C. (2016). Ecological and Pharmacological Activities of Antarctic Marine Natural Products. *Planta Medica, 82*, 767 - 774.
28. Núñez-Pons, L., & Ávila, C. (2015). Natural products mediating ecological interactions in Antarctic benthic communities: a mini-review of the known molecules. *Natural product reports, 32 7*, 1114-30 .
29. Albericio F, Álvarez M, Cuevas C, Francesch A, Pla D, Tulla-Puche J. The sea as a source of new drugs. In: Tamaki N, Kuge Y, editors. Molecular imaging for integrated medical therapy and drug development. Tokyo: Springer Japan; 2010: 237–249
30. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311–335
31. Lebar MD, Heimbegner JL, Baker BJ. Cold-water marine natural products. Nat Prod Rep 2007; 24: 774–797
32. Blunt JW, Copp BR, Keyzers R, Munro MHG, Prinsep MR. Marine natural products. Nat Prod Rep 2014; 31: 160–258
33. Avila C, Taboada S, Núñez-Pons L. Antarctic marine chemical ecology: what is next? Mar Ecol 2008; 29: 1–71
34. Taboada S, Núñez-Pons L, Avila C. Feeding repellence of Antarctic and sub-Antarctic benthic invertebrates against the omnivorous seastar Odontaster validus. Polar Biol 2013; 36: 13–25
35. Clarke A, Johnston NM. Antarctic marine benthic diversity. Oceanogr Mar Biol Ann Rev 2003; 41: 47–114
36. Tin, T., Fleming, Z.L., Hughes, K.A., Ainley, D.G., Convey, P., Moreno, C.A., Pfeiffer, S., Scott, J., & Snape, I. (2008). Impacts of local human activities on the Antarctic environment. *Antarctic Science, 21*, 3 - 33.
37. Reyes F, Fernández R, Rodríguez A, Francesch A, Taboada S, Avila C, Cuevas C. Aplicyanins A–F, new cytotoxic bromoindole derivatives from the marine tunicate Aplidium cyaneum. Tetrahedron 2008; 64: 5119–5123
38. Mayer AM, Pierce ML, Howe K, Rodríguez AD, Taglialatela-Scafati O, Nakamura F, Fusetani N. Marine pharmacology in 2018: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Pharmacological Research. 2022 Sep 1;183:106391.
39. Brunati M, Rojas JL, Sponga F, Ciciliato I, Losi D, Göttlich E, de Hoog S, Genilloud O, Marinelli F. Diversity and pharmaceutical screening of fungi from benthic mats of Antarctic lakes. Marine genomics. 2009 Mar 1;2(1):43-50.
40. Godinho VM, Furbino LE, Santiago IF, Pellizzari FM, Yokoya NS, Pupo D, Alves TM, S Junior PA, Romanha AJ, Zani CL, Cantrell CL. Diversity and bioprospecting of fungal communities associated with endemic and cold-adapted macroalgae in Antarctica. The ISME journal. 2013 Jul;7(7):1434-51.
41. Loque CP, Medeiros AO, Pellizzari FM, Oliveira EC, Rosa CA, Rosa LH. Fungal community associated with marine macroalgae from Antarctica. Polar Biology. 2010 May;33:641-8.
42. Taboada S, García-Fernández LF, Bueno S, Vázquez J, Cuevas C, Avila C. Antitumoural activity in Antarctic and sub-Antarctic benthic organisms. Ant Sci 2010; 22: 494–507
43. Shimizu K, Kondo R, Sakai K, Takeda N, Nagahata T, Oniki T. 2001. Novel vitamin E derivative with 4-substituted resorcinol moiety has both antioxidant and tyrosinase inhibitory properties. Lipids **36**: 1321–1326.
44. Bhattarai HD, Paudel B, Lee HS, Lee YK, Yim JH. Antioxidant activity of Sanionia uncinata, a polar moss species from King George Island, Antarctica. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2008 Dec;22(12):1635-9.
45. Fernandes AS, Mazzei JL, Oliveira CG, Evangelista H, Marques MR, Ferraz ER, Felzenszwalb I. Protection against UV-induced toxicity and lack of mutagenicity of Antarctic Sanionia uncinata. Toxicology. 2017 Feb 1;376:126-36.
46. SCHMITZ, F.J., BOWDEN, B.F. & TOTH, S.I. 1993. Antitumor and cytotoxic compounds from marine organisms. In ATTAWAY, D.H. & ZABORSKY, O.K., eds. Marine biotechnology, pharmaceutical and bioactive natural products. New York: Plenum Press, 197–308.
47. MUNRO, M.H.G., BLUNT, J.W., DUMDEI, E.J., HICKFORD, S.J.H., LILL, R.E., LI, S., BATTERSHILL, C.N. & DUCKWORTH, A.R. 1999. The discovery and development of marine compounds with pharmaceutical potential. Journal of Biotechnology, **70**, 15–25.
48. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J. 2006;27:107–113.
49. Njølstad I, Arnesen E, Lund-Larsen PG. Cardiovascular diseases and diabetes mellitus in different ethnic groups: the Finnmark study. Epidemiology. 1998;9:550–556.
50. Norum J, Hovland A, Balteskard L, Trovik T, Haug B, Hansen FH, Alterskjær S, Madsen P, Olsen F. Treatment of acute myocardial infarction in the sub-arctic region of Norway. Do we offer an equal quality of care?. International Journal of Circumpolar Health. 2017 Jan 1;76(1):1391651.
51. DE DIEGO-LUSA F, RODRIGO-ARRASTIO CF, PÉREZ-AZUARA F, SÁNCHEZ-MARTÍN DE LA PEÑA R. La Sanidad en la Base Antártica del E.T. “Gabriel de Castilla”. Sanid mil 2011; 67 (2): 115-26.
52. LISBONA-GIL A. Ser médico en la Antártida. Rev Clin Esp 2010; 210 (3): 141-4.
53. FERNÁNDEZ-RIESTRA FA. Las investigaciones médicas de la Armada en la Antártida. Revista General de Marina 2009; 3: 91-100.
54. SOTERAS-MARTÍNEZ I, SERÓN-ARBELOA C, AVELLANASCHAVALA M, FÁCIL-CARMEN JM. Medicina antártica en el año 2008: Año Polar Internacional y 20º aniversario de la Base Antártica Española. Med Clin (Barc) 2009; 132 (17): 677-81.
55. BENDALA-AYUSO A. Asistencia Sanitaria en la Base Antártica Gabriel de Castilla. Revista Ejército. 157-8.
56. LUGG DJ. Head of Environmental Medicine. NASA, 2006, Comunicación Personal.
57. PEÑATO-LUENGO F, NAVARRO-SUAY R, DÍEZ-NAVARRO N, PUENTE-AGUEDA P, Spain EL. Could You Use Anaesthetic Drugs in Antarctica? Research on Pharmacological Effectiveness. ARMED FORCES MEDICAL SERVICES.:50.
58. Roth DE, Abrams SA, Aloia J, et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann N Y Acad Sci. 2018;1430(1):44–79.
59. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357 (3):266–281.
60. Edvardsen K, Brustad M, Engelsen O, et al. The solar UV radiation level needed for cutaneous production of vitamin D3 in the face. A study conducted among subjects living at a high latitude (68 degrees N). Photochem Photobiol Sci. 2007;6(1):57–62.
61. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67(2):373–378.
62. Bais AF, Lucas RM, Bornman JF, et al. Environmental effects of ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2017. Photochem Photobiol Sci. 2018;17(2):127–179.
63. Cordero RR, Damiani A, Seckmeyer G, et al. Satellite- derived UV climatology at Escudero Station, Antarctic Peninsula. Antarctic Science. 2013;25(6):791–803.
64. Iuliano S, Ayton J. Dietary intakes of expeditioners during prolonged sunlight deprivation in polar enviroments do not support bone health. Int J Circumpolar Health. 2015;74(1):27965.
65. Cabalín C, Iturriaga C, Pérez-Mateluna G, Echeverría D, Camargo Jr CA, Borzutzky A. Vitamin D status and supplementation in Antarctica: a systematic review and meta-analysis. International Journal of Circumpolar HeaEven though the speed witlth. 2021 Jan 1;80(1):1926133.
66. Steinach M, Kohlberg E, Maggioni MA, Mendt S, Opatz O, Stahn A, Tiedemann J, Gunga HC. Changes of 25-OH-vitamin D during overwintering at the German Antarctic Stations Neumayer II and III. PloS one. 2015 Dec 7;10(12):e0144130.
67. Smith SM, Gardner KK, Locke J, Zwart SR. Vitamin D supplementation during Antarctic winter. The American journal of clinical nutrition. 2009 Apr 1;89(4):1092-8.
68. Cabalín C, Iturriaga C, Pérez-Mateluna G, Echeverría D, Camargo CA Jr, Borzutzky A. Vitamin D status and supplementation in Antarctica: a systematic review and meta- analysis. Int J Circumpolar Health. 2021 Dec;80(1):1926133. doi: 10.1080/22423982.2021.1926133. PMID: 33983101; PMCID: PMC8128169.
69. Gutiérrez, J., González-Acuña, D., Fuentes-Castillo, D., Fierro, K., Hernández, C., Zapata, L., & Verdugo, C. (2024). Antibiotic resistance in wildlife from Antarctic Peninsula. *The Science of the total environment*, 170340 .
70. White A, Hughes JM. Critical importance of a One Health approach to antimicrobial resistance. Ecohealth. 2019;16(3):404–9.
71. Scott LC, Lee N, Aw TG. Antibiotic resistance in minimally humanimpacted environments. Int J Environ Res Public Health. 2020;17(11):3939.
72. Hwengwere K, Paramel Nair H, Hughes KA, Peck LS, Clark MS, Walker CA. Antimicrobial resistance in Antarctica: is it still a pristine environment?. Microbiome. 2022 May 6;10(1):71.
73. Council of Managers of National Antarctic Programs. Antarctic station catalogue. COMNAP Secretariat; 2017.
74. Segawa T, Ushida K, Narita H, Kanda H, Kohshima S. Bacterial communities in two Antarctic ice cores analyzed by 16S rRNA gene sequencing analysis. Polar Sci. 2010;4(2):215–27.
75. Hwengwere K, Paramel Nair H, Hughes KA, Peck LS, Clark MS, Walker CA. Antimicrobial resistance in Antarctica: is it still a pristine environment?. Microbiome. 2022 May 6;10(1):71. `
76. Okubo T, Ae R, Noda J, Iizuka Y, Usui M, Tamura Y. Detection of the sul2-strA-strB gene cluster in an ice core from Dome Fuji Station, East Antarctica. J Glob Antimicrob Resist. 2019;17:72–8.
77. Miller RV, Gammon K, Day MJ. Antibiotic resistance among bacteria isolated from seawater and penguin fecal samples collected near Palmer Station, Antarctica. Canadian journal of microbiology. 2009 Jan;55(1):37-45.
78. De Souza MJ, Bharathi PAL, Nair S, Chandramohan D. “Trade-off” in Antarctic bacteria: limnetic psychrotrophs concede multiple enzyme expressions for multiple metal resistance. Biometals. 2007;20(6):821–8.
79. Azarov II, Butakov SS, Zholus BI, Zetkin AYu, Remmer VN. Opyt soxraneniya zdorov'ya voennosluzhashhix v Arktike v povsednevnoj deyatel'nosti i chrezvychajnyx situaciyax. Morskaya medicina. 2017; 3 (3): 102–111. Russian.
80. Kazakevich EV, Arxipovskij VL, Sereda AP, Abakumov AA. Osobennosti organizacii medicinskoj pomoshhi moryakam v usloviyax Arktiki. Medicina ehkstremal'nyx situacij. 2017; 4 (62): 15–20. Russian.
81. Dimov SG, Strateva T. Detection of clinically relevant antimicrobial resistance determinants in warm-blooded marine animals in Livingston Island (South Shetland Islands, Antarctica): A field-based molecular genetics study. Marine Pollution Bulletin. 2022 Jul 1;180:113751
82. Golubev VN, Korolev YuN, Belokopytova EV. Individual'naya strategiya adaptacii dyxatel'noj sistemy cheloveka kak reakciya na gipoksicheskuyu gipoksiyu. Izvestiya Rossijskoj Voenno-medicinskoj akademii. 2019; 38 (3): 172–7. Russian.
83. Volkova MV, Biryukov SA. METHODOLOGICAL ASPECTS OF DRUG DEVELOPMENT AND PRECLINICAL RESEARCH IN THE INTERESTS OF ARTIC MEDICINE.
84. Giordano D. Bioactive molecules from extreme environments. Marine drugs. 2020 Dec 14;18(12):640.
85. Singh A, Singh KS. Bioactive compounds from polar regions: an account of chemical ecology and biotechnological applications. Current Organic Chemistry. 2022 Jun 1;26(11):1055-87.
86. Volkova MV, Biryukov SA. METHODOLOGICAL ASPECTS OF DRUG DEVELOPMENT AND PRECLINICAL RESEARCH IN THE INTERESTS OF ARTIC MEDICINE.